Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Racemethorphan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A known ✓ | Q12879 | 8/20 | 1.00 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 6/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 8/20 | 1.00 |
| ▸ | GRIN2D | O15399 | 7/20 | 1.00 |
| ▸ | GRIN3B | O60391 | 7/20 | 1.00 |
| ▸ | GRIN2B | Q13224 | 7/20 | 1.00 |
| ▸ | GRIN2C | Q14957 | 7/20 | 1.00 |
| ▸ | GRIN3A | Q8TCU5 | 7/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 7/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 5/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 4/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racemethorphan SCHEMBL503864 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Dextromethorphan SCHEMBL29949 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Levomethorphan SCHEMBL29950 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL22722074 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL4167360 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL503878 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL14579836 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL20808854 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL20809259 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Racemethorphan SCHEMBL21095577 | 1.00 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535596-B2 | Analogs of dextromethorphan with balanced receptor activities | CENTER FOR NEUROLOGIC STUDY (US) | 2022-12-27 | — | — | US | disclosed |
| WO-2022253353-A1 | PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYNIONE AND DEXTROMETHORPHAN AND APPLICATION THEREOF IN TREATING PULMONARY FIBROSIS | 北京康蒂尼药业股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| US-10865187-B2 | Methods for the synthesis of deuterated dextromethorphan | AVANIR PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| WO-2019049918-A1 | INDUSTRIAL PROCESS OF MONO-ALKYLATING A PIPERIDINE NITROGEN IN PIPERIDINE DERIVATIVES WITH DEUTERATED-ALKYL | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-03-14 | — | — | WO | disclosed |
| US-20120226043-A1 | METHOD FOR THE N-DEMETHYLATION OF N-METHYL HETEROCYCLES | MONASH UNIVERSITY (AU) | 2012-09-06 | — | — | US | disclosed |
| US-20100197661-A1 | Method of Treating Neurological Diseases and Disorders | DREYFUSS GIDEON | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865187-B2 | Methods for the synthesis of deuterated dextromethorphan | CYP2D6, OPRD1, OPRK1 | GRIN2A 337/4885SIGMAR1 65/4885GRIN1 353/4885 |
| US-20100197661-A1 | Method of Treating Neurological Diseases and Disorders | SMN1; SMN2, CLN6, PMP22 | GRIN2A 192/4885SIGMAR1 3625/4885GRIN1 679/4885 |
| US-11535596-B2 | Analogs of dextromethorphan with balanced receptor activities | SIGMAR1, OPRM1, OPRD1 | GRIN2A 34/4885SIGMAR1 1/4885GRIN1 16/4885 |
| US-20120226043-A1 | METHOD FOR THE N-DEMETHYLATION OF N-METHYL HETEROCYCLES | TET3, DNMT1, TET2 | GRIN2A 1212/4885SIGMAR1 3185/4885GRIN1 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.